GeneDx Holdings Corp. (WGS)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$69.34+1.02%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · WGS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 386.3% |
| Our one-year growth estimate | diamond | 27.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 359.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 13 industry peers
WGS — earnings miss
Dated 2026-05-04
Results of Operations and Financial Condition. Financial Results for the Quarter Ended March 31, 2026 On May 4, 2026 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended March 31, 2026 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.3, respectively, to this Current Report on Form 8-K. Consolidated Statements of Operation…
Why it matters: GeneDx cut its 2026 revenue outlook in Q1 and kept it in Q2. Q3 revenue tests whether the new plan is holding.
Worry ifQ3 revenue is below $122 million, the low end of the stated $122 million to $124 million range.
Less concerning ifQ3 revenue is at least $122 million and full-year guidance stays at $475 million to $490 million.
Why it matters: New Medicaid and Carelon coverage can open testing to more patients. The company named coverage growth as a priority, but access gains need proof in results.
Supportive ifGeneDx names an insurer or state Medicaid program that covers outpatient exome or genome tests. It then reports higher test volume tied to access.
Worry ifGeneDx reports no new coverage wins and exome and genome volume growth falls below 30% year over year.
Why it matters: That is the Q3 test volume target. A miss would weaken the case for at least 30% growth in 2026.
Worry ifOn the November 9 earnings call, GeneDx reports fewer than 33,200 exome and genome tests for Q3.
Less concerning ifGeneDx reports 33,200 or more exome and genome tests for Q3.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$306 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $785 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,940 loss on $10,000 · 79.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.